What is InteloMed?
InteloMed is a specialized medical technology firm focused on redefining the standard of care through its intelligent, multi-dimensional CVInsight® Patient Monitoring & Informatics System. By providing real-time, non-invasive physiologic insights, the company empowers clinicians to proactively manage cardiovascular stress, particularly during dialysis treatments. The system utilizes patented, proprietary algorithms to deliver actionable alerts, effectively mitigating the risks associated with dialysis interruptions. With FDA clearance and CE marking, InteloMed has successfully transitioned from a development-stage entity to a commercial-stage provider, currently operating out of its headquarters in Wexford, Pennsylvania.
How much funding has InteloMed raised?
InteloMed has raised a total of $16.7M across 7 funding rounds:
Private Equity
$2.6M
Series A
$4M
Private Equity
$3.8M
Private Equity
$1.9M
Debt
$502K
Debt
$47K
Other Financing Round
$3.8M
Private Equity (2011): $2.6M, investors not publicly disclosed
Series A (2013): $4M, investors not publicly disclosed
Private Equity (2014): $3.8M, investors not publicly disclosed
Private Equity (2016): $1.9M, investors not publicly disclosed
Debt (2016): $502K, investors not publicly disclosed
Debt (2021): $47K with participation from PPP
Other Financing Round (2025): $3.8M, investors not publicly disclosed
Key Investors in InteloMed
Undisclosed Investor
An institutional capital partner focused on supporting high-growth medical technology firms through strategic equity financing.
PPP
Public-Private Partnership
Undisclosed Investor
A strategic backer specializing in early-to-mid stage healthcare innovation and medical device commercialization.
What's next for InteloMed?
With the recent influx of capital, InteloMed is well-positioned to accelerate its commercial footprint and deepen its penetration into the clinical monitoring market. The strategic focus will likely shift toward expanding the clinical utility of the CVInsight® system, potentially exploring new applications for its proprietary algorithms in broader cardiovascular diagnostics. As the company navigates this phase of enterprise-level growth, the emphasis remains on enhancing operational efficiency and strengthening its competitive moat through continued innovation in patient informatics. Future milestones will likely involve scaling sales infrastructure and pursuing additional regulatory validations to support long-term market adoption.
See full InteloMed company page
